,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-02-11 03:45:00,Warner Chilcott ( WCRX ) recently revealed its financial guidance for 2013.,0.05249842256307602,0.00792656373232603,0.9395749568939209,neutral,0.044571857899427414
1,2013-02-11 03:45:00,The company expects to earn $3.20-$3.30 per share on total revenues of $2.3-$2.4 billion in 2013.,0.2932671904563904,0.012240824289619923,0.694491982460022,neutral,0.28102636337280273
2,2013-02-11 03:45:00,"While revenue guidance was in line with expectations, earnings guidance missed it with the Zacks Consensus Estimate standing at $3.60 per share.",0.07206866890192032,0.8764980435371399,0.051433295011520386,negative,-0.8044293522834778
3,2013-02-11 03:45:00,"The guidance assumes continued sales erosion of its osteoporosis drug, Actonel.",0.06669462472200394,0.8407912850379944,0.09251416474580765,negative,-0.774096667766571
4,2013-02-11 03:45:00,"We remind investors that Actonel - acquired from Procter & Gamble Company ( PG ) in 2009 - went off-patent in Western Europe in late 2010, thus significantly hampering revenues at Warner Chilcott.",0.019999083131551743,0.9682620763778687,0.011738775297999382,negative,-0.9482629895210266
5,2013-02-11 03:45:00,Actonel accounted for 70% of the company's 2010 revenues from the region.,0.03379944711923599,0.007553160190582275,0.9586474299430847,neutral,0.026246286928653717
6,2013-02-11 03:45:00,"Moreover, the contraction of the US bisphosphonate market is expected to hamper US Actonel sales in 2013.",0.020000968128442764,0.9663582444190979,0.01364079862833023,negative,-0.946357250213623
7,2013-02-11 03:45:00,"However, Warner Chilcott expects products, such as Lo Loestrin FE (oral contraceptive) and Estrace Cream (hormone therapy) to perform well in 2013.",0.9344204068183899,0.01465018279850483,0.05092931538820267,positive,0.9197702407836914
8,2013-02-11 03:45:00,The addition of ulcerative colitis drug Delzicol - approved earlier in the month and expected to be launched next month - to the company's product portfolio should also augment its top line.,0.9320548176765442,0.013781157322227955,0.05416408181190491,positive,0.9182736873626709
9,2013-02-11 03:45:00,We are positive on the addition of the new product to Warner Chilcott's product portfolio since many of its key drugs are facing declining sales due to generic competition.,0.5921275615692139,0.11060746759176254,0.297264963388443,positive,0.4815200865268707
10,2013-02-11 03:45:00,The generic competition that Warner Chilcott is currently facing or expects to face for its various drugs has put significant pressure on it.,0.02483551762998104,0.8898223638534546,0.08534222096204758,negative,-0.8649868369102478
11,2013-02-11 03:45:00,"Warner Chilcott expects selling, general and administrative (SG&A) expense in 2013 in the range of $750-$800 million (2012 expectation: $725-$775 million).",0.019809845834970474,0.18107059597969055,0.7991195321083069,neutral,-0.16126075387001038
12,2013-02-11 03:45:00,Research and development (R&D) expenses in 2012 are expected in the range of $115-$135 million (2012 expectation: $90-$110 million).,0.019501471891999245,0.04972751811146736,0.930770993232727,neutral,-0.030226046219468117
13,2013-02-11 03:45:00,Warner Chilcott currently carries a Zacks Rank #3 (Hold).,0.03437071293592453,0.019221840426325798,0.9464074373245239,neutral,0.015148872509598732
14,2013-02-11 03:45:00,Valeant Pharmaceuticals ( VRX ) and United Therapeutics ( UTHR ) are well placed in the pharmaceutical space with a Zacks Rank #1 (Strong Buy).,0.8665940761566162,0.016669221222400665,0.11673673242330551,positive,0.8499248623847961
15,2013-02-11 03:45:00,To read this article on Zacks.com click here.,0.01796119473874569,0.0192450862377882,0.9627937078475952,neutral,-0.001283891499042511
16,2013-02-11 03:45:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
